Signal Transduction And Targeted Therapy impact factor, indexing, ranking (2024)

Aim and Scope

The Signal Transduction And Targeted Therapy is a research journal that publishes research related to Biochemistry, Genetics and Molecular Biology. This journal is published by the Springer Nature. The ISSN of this journal is 20593635, 20959907. Based on the Scopus data, the SCImago Journal Rank (SJR) of signal transduction and targeted therapy is 6.63.

Also, please check the following important details about signal transduction and targeted therapy: Publisher, ISSN, Ranking, Indexing, Impact Factor (if applicable), Publication fee (APC), Review Time, and Acceptance Rate.

According to Clarivate's JCR, journals indexed in SCIE/SSCI have an impact factor.

Signal Transduction And Targeted Therapy Ranking

Impact Factor: 38.104

Total Citations: 11026

SJR (SCImago Journal Rank): 6.63

Quartile: Q1

The Impact Factor of Signal Transduction And Targeted Therapy is 38.104.

The impact factor (IF) is a measure of the frequency with which the average article in a journal has been cited in a particular year. It is used to measure the importance or rank of a journal by calculating the times its articles are cited.

The impact factor was devised by Eugene Garfield, the founder of the Institute for Scientific Information (ISI) in Philadelphia. Impact factors began to be calculated yearly starting from 1975 for journals listed in the Journal Citation Reports (JCR). ISI was acquired by Thomson Scientific & Healthcare in 1992, and became known as Thomson ISI. In 2018, Thomson-Reuters spun off and sold ISI to Onex Corporation and Baring Private Equity Asia. They founded a new corporation, Clarivate, which is now the publisher of the JCR.

Important Metrics

Journal Title:	Signal Transduction and Targeted Therapy
Publisher:	Springer Nature
ISSN:	20593635, 20959907
Type:	journal
Journal Scope:	Biochemistry, Genetics and Molecular Biology
Country:	United Kingdom
H-Index:	83
SJR:	6.63
Quartile:	Cancer Research (Q1); Genetics (Q1)

signal transduction and targeted therapy Indexing

The signal transduction and targeted therapy is indexed in:

UGC CARE
Scopus
Web of Science (SCIE)
DOAJ
PubMed

An indexed journal means that the journal has gone through and passed a review process of certain requirements done by a journal indexer.

The Web of Science Core Collection includes the Science Citation Index Expanded (SCIE), Social Sciences Citation Index (SSCI), Arts & Humanities Citation Index (AHCI), and Emerging Sources Citation Index (ESCI).

Signal Transduction And Targeted Therapy Impact Factor 2024

The latest impact factor of signal transduction and targeted therapy is 38.104.

The impact factor (IF) is a measure of the frequency with which the average article in a journal has been cited in a particular year. It is used to measure the importance or rank of a journal by calculating the times it's articles are cited.

Note: Every year, The Clarivate releases the Journal Citation Report (JCR). The JCR provides information about academic journals including impact factor. The latest JCR was released in June, 2023. The JCR 2024 will be released in the June 2024.

Signal Transduction And Targeted Therapy Quartile

The latest Quartile of signal transduction and targeted therapy is Q1.

Each subject category of journals is divided into four quartiles: Q1, Q2, Q3, Q4. Q1 is occupied by the top 25% of journals in the list; Q2 is occupied by journals in the 25 to 50% group; Q3 is occupied by journals in the 50 to 75% group and Q4 is occupied by journals in the 75 to 100% group.

Publication fee

According to journal website, the publication fee of signal transduction and targeted therapy is around 2690 EUR; 3190 USD; 2390 GBP.

The signal transduction and targeted therapy has also Journal waiver policy (for developing countries, authors etc).

An article processing charge (APC), also known as a publication fee, is a fee which is sometimes charged to authors. Most commonly, it is involved in making a work available as open access (OA), in either a full OA journal or in a hybrid journal.

Call for Papers

Visit to the official website of the journal/ conference to check the details about call for papers.

How to publish in Signal Transduction And Targeted Therapy?

If your research is related to Biochemistry, Genetics and Molecular Biology, then visit the official website of signal transduction and targeted therapy and send your manuscript.

Tips for publishing in Signal Transduction And Targeted Therapy:

Selection of research problem.
Presenting a solution.
Designing the paper.
Make your manuscript publication worthy.
Write an effective results section.
Mind your references.

Acceptance Rate

Acceptance rate is the ratio of the number of articles submitted to the number of articles published. Researchers can check the acceptance rate on the journal website. Alternatively, they can contact the editor of the journal.

Journal Publication Time

The Journal Publication Time means the average number of weeks between article submission and publication. According to the journal website, the signal transduction and targeted therapy publishes research articles in 5 weeks on an average.

Final Summary

The impact factor of signal transduction and targeted therapy is 38.104.
The signal transduction and targeted therapy is a reputed research journal.
It is published by Springer Nature.
The journal is indexed in UGC CARE, Scopus, SCIE, DOAJ, PubMed.
It is an open access journal.
The (SJR) SCImago Journal Rank is 6.63.
The publication time (Average number of weeks between article submission and publication) of the journal is 5 weeks.
The Publication fee (APC) signal transduction and targeted therapy 2690 EUR; 3190 USD; 2390 GBP.